Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients.

Flaminia OlearoHuyen NguyenFabrice BonnetSabine YerlyGilles WandelerMarcel StoeckleMatthias CavassiniAlexandra ScherrerDominique CostagliolaPatrick SchmidHuldrych F GünthardEnos BernasconiJürg BoeniAntonella D'arminio MonforteMaurizio ZazziBarbara RossettiDidier NeauPantxika BellecaveBart RijndersPeter ReissFerdinand WitRoger KouyosAlexandra Calmy

Published in: Open forum infectious diseases (2019)

[This corrects the article DOI: 10.1093/ofid/ofz330.][This corrects the article DOI: 10.1093/ofid/ofz330.].

Keyphrases

antiretroviral therapy
end stage renal disease
hiv infected patients
ejection fraction
newly diagnosed
chronic kidney disease
hiv infected
human immunodeficiency virus
hiv positive
peritoneal dialysis
prognostic factors
hepatitis c virus
hiv aids
hiv testing
mesenchymal stem cells